Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1534179
This article is part of the Research Topic Community Series in Reducing Adverse Effects of Cancer Immunotherapy: Volume II View all 17 articles

Sintilimab for the Treatment of Lung Adenocarcinoma-Induced Immune-Related Hypophysitis: A Case Report

Provisionally accepted
Mingxing Wang Mingxing Wang Aixin Liu Aixin Liu Qingming Sun Qingming Sun Wanhui Dong Wanhui Dong *
  • Anhui University of Chinese Medicine, Hefei, China

The final, formatted version of the article will be published soon.

    Immune checkpoint inhibitors (ICIs) are extensively utilized in the treatment of oncological patients, and the immune-related adverse reactions they induce merit close monitoring. This report describes a case of a lung cancer patient who, after receiving chemotherapy in combination with the programmed death-1 (PD-1) inhibitor sintilimab, presented with systemic fatigue, alterations in mental and behavioral patterns, somnolence, and symptoms of diabetes insipidus, leading to a diagnosis of grade 4 immune-related hypophysitis. The patient experienced symptomatic relief following pulse therapy with dexamethasone sodium phosphate injections (30mg every 12 hours), and was subsequently treated with prednisone acetate tablets (30 mg/day), which were gradually reduced to a physiological replacement dose. The treatment with sintilimab was discontinued, and the patient's symptoms gradually improved, with normalization of urine output.

    Keywords: Sintilimab, hypophysitis, Diabetes Insipidus, Adverse Reactions, immune checkpoint inhibitors

    Received: 25 Nov 2024; Accepted: 06 Jan 2025.

    Copyright: © 2025 Wang, Liu, Sun and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wanhui Dong, Anhui University of Chinese Medicine, Hefei, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.